Coya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder Purchases 1,800 Shares

Coya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder purchased 1,800 shares of Coya Therapeutics stock in a transaction that occurred on Thursday, November 14th. The stock was bought at an average cost of $7.19 per share, for a total transaction of $12,942.00. Following the purchase, the chief financial officer now directly owns 8,800 shares in the company, valued at $63,272. This trade represents a 25.71 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Coya Therapeutics Price Performance

COYA opened at $6.32 on Friday. Coya Therapeutics, Inc. has a 12 month low of $4.75 and a 12 month high of $10.69. The stock has a fifty day moving average price of $7.12 and a 200-day moving average price of $6.99.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. Analysts expect that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of COYA. Vanguard Group Inc. grew its holdings in Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares during the last quarter. Gilbert & Cook Inc. acquired a new stake in shares of Coya Therapeutics in the 2nd quarter worth $61,000. Renaissance Technologies LLC purchased a new position in Coya Therapeutics during the 2nd quarter worth $101,000. GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics during the 3rd quarter valued at about $169,000. Finally, Geode Capital Management LLC increased its position in Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after buying an additional 4,485 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on COYA. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday, November 11th. Chardan Capital reiterated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.